Maxim analyst Jason McCarthy downgraded Vistagen (VTGN) to Hold from Buy after the company announced that the PALISADE-3 Phase 3 study of intranasal fasedienol for the acute treatment of social anxiety disorder did not demonstrate a statistically significant improvement on its primary endpoint.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTGN:
- Vistagen downgraded to Market Perform from Outperform at William Blair
- Vistagen downgraded to Market Perform at William Blair after PALISADE-3 miss
- Vistagen downgraded to Hold at Stifel after PALISADE-3 study disappoints
- Vistagen downgraded to Hold from Buy at Stifel
- Vistagen downgraded to Neutral from Buy at Lucid Capital